Reversine, a small synthetic purine analogue (2, 6-disubstituted purine), is a potent inhibitior of Aurora A/B/C(IC50s=150-500 nM).

Aurora A:150-500 nM, Aurora B:150-500 nM, Aurora C:150-500 nM

In mice carrying U14 tumors, intraperitoneal injection of Reversine (10 mg/kg) effectively reduces tumor cells.

In stably transfected Chinese hamster ovary cells, Reversine can competitively inhibit cAMP production stimulated by. In HCT116 cells, Reversine suppresses the Aurora targets and phosphorylation of histone H3. Additionally, in primary human tumor samples, Reversine is capable of inhibiting the formation of leukemia cell colonies.

Radioligand Binding Assays: Each tube in the A3 AR competitive binding assay contains 100 μL of membrane suspension (20 μg of protein), 50 μL of [125I]4-amino-3-iodobenzyl)adenosine-5′-N-methyluronamide (0.5 nM), and 50 μL of increasing concentrations of the test ligands in Tris-HCl buffer (50 mM, pH 7.4) containing 10 mM MgCl2 and 1 mM EDTA. Nonspecific binding is determined using 10 mM 5′-N-ethylcarboxamidoadenosine in the buffer. The mixtures are incubated at 25°C for 60 min. Binding reactions are terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester. Filters are washed three times with 9 mL of ice-cold buffer. Radioactivity is determined using a Beckman γ-counter, and the percent inhibition is calculated.

Cell viability of different tumor cell lines is assessed using ATPlite 1step. Briefly, 2 × 104?cells for each well are plated in a 96-well plate in presence of crescent quantity of reversine. After 72 h, the plates are recovered and 100 μL ATPlite solution is added to each well. The plates are shaken for 2 min at 700 rpm and luminescence is measured using EnVision Multilabel plate reader. Each sample is analyzed in triplicate.(Only for Reference)